Atul Ltd: A Deep Dive into India's Diversified Specialty Chemicals Pioneer

Equity Research Report | NiftyBrief | June 2026

Company Overview

Atul Ltd (NSE: ATUL, BSE: 500027) is one of India's oldest and most diversified integrated chemical companies, operating under the umbrella of the Lalbhai Group — one of Gujarat's most storied business dynasties. Incorporated in 1947 as Atul Products Ltd by the late Padma Bhushan Kasturbhai Lalbhai, the company was renamed Atul Ltd in 1996. Remarkably, it was the first company in India to be inaugurated by the country's first Prime Minister, Jawaharlal Nehru.

The company operates across two major segments — Life Science Chemicals and Performance and Other Chemicals — spanning nine distinct business verticals. Its product portfolio includes agrochemicals, aromatics, bulk chemicals, colours, epoxy resins, phosgene derivatives, pharmaceutical intermediates, and specialty polymers. Since its inception, Atul has been a pioneer, manufacturing numerous products for the first time in India, including Vat Dyes, crop care chemicals, Phosgene, Carbamite, 2,4-D Acid, para Cresol, and even tissue culture raised date palms.

Originally a B2B company, Atul has in recent years ventured into B2C products, broadening its addressable market. The company's manufacturing facilities are primarily located in Atul, Gujarat, with additional sites across India.

Key Financial Metrics at a Glance

Revenue & Profitability: A Consistent Growth Story

Annual Financial Performance (FY2015–FY2026)

Atul's revenue trajectory over the past decade tells a story of steady, if unspectacular, growth punctuated by cyclical headwinds and recoveries.

Key observations:

• Revenue has grown from ₹2,637 Cr in FY2015 to ₹6,274 Cr in FY2026, a CAGR of approximately 9% over 10 years.
• The 5-year revenue CAGR stands at 11%, while the 3-year CAGR is 5%, reflecting the cyclical downturn in FY2024.
• Operating margins have fluctuated between 14% and 25%, with FY2021 marking the peak at 25% during the post-COVID commodity upcycle.
• Net profit peaked at ₹671 Cr in FY2020, bottomed at ₹324 Cr in FY2024, and has since recovered sharply to ₹689 Cr in FY2026 — an all-time high.
• EPS has mirrored profit trends, ranging from ₹81.13 in FY2015 to ₹230.25 in FY2026.
• Dividend payout has been conservative, ranging from 9% to 19%, with FY2026 at 13%.

Compounded Growth Rates

The TTM profit growth of 39% is particularly noteworthy, signalling a strong earnings recovery. However, the negative 5-year stock price CAGR of -4% suggests the market has yet to fully re-rate the stock.

Quarterly Performance: Momentum Building

The quarterly data reveals an accelerating trend in both revenue and profitability, particularly over the last four quarters.

Highlights:

• Revenue has grown from ₹1,195 Cr in Q4 FY2023 to ₹1,670 Cr in Q4 FY2026, a ~40% increase over 12 quarters.
• Operating profit has nearly doubled from ₹149 Cr to ₹281 Cr in the same period.
• Operating margins have improved from 12% to 17%, reflecting operating leverage and better product mix.
• Net profit surged from ₹59 Cr in Q4 FY2024 (the trough) to ₹211 Cr in Q4 FY2026 — a 258% jump in just two years.
• The most recent quarter (Q4 FY2026) delivered the highest-ever quarterly revenue of ₹1,670 Cr and the highest-ever quarterly net profit of ₹211 Cr.
• Other income surged to ₹92 Cr in Q4 FY2026 (from ₹16–28 Cr in prior quarters), possibly indicating treasury gains or dividend income from subsidiaries.

Balance Sheet: Strong and Largely Debt-Free

Atul's balance sheet reflects a conservatively managed, asset-rich company with minimal leverage.

Key balance sheet takeaways:

• Reserves have grown from ₹1,009 Cr in FY2015 to ₹6,192 Cr in FY2026, reflecting consistent retained earnings.
• Borrowings are minimal at just ₹183 Cr against total assets of ₹7,900 Cr, making the company virtually debt-free with a debt-to-equity ratio of approximately 0.03x.
• Investments have surged to ₹2,592 Cr in FY2026 (from ₹66 Cr in FY2015), indicating substantial capital allocation to subsidiaries, mutual funds, or strategic investments.
• Fixed assets peaked at ₹2,847 Cr in FY2025 and moderated to ₹2,676 Cr in FY2026, while CWIP has declined to ₹110 Cr, suggesting the capex cycle is maturing.
• Total equity (capital + reserves) stands at ₹6,221 Cr, translating to a book value per share of approximately ₹2,113.

Cash Flow: Healthy and Improving

Key cash flow observations:

• Cash from operations (CFO) surged to ₹1,023 Cr in FY2026, the highest ever, reflecting the strong earnings recovery.
• Free cash flow (FCF) of ₹851 Cr in FY2026 is exceptional, indicating the company is generating significant surplus cash after all capital expenditure.
• The CFO/Operating Profit ratio of 114% in FY2026 indicates high-quality earnings with good cash conversion.
• FY2022 and FY2023 saw negative FCF due to heavy capex (₹420 Cr and ₹1,033 Cr in CWIP respectively), but this investment is now bearing fruit.
• The improvement in FCF from -₹359 Cr in FY2022 to +₹851 Cr in FY2026 is a dramatic turnaround.

Operating Ratios: Efficiency Under Watch

Key observations:

• ROCE has recovered from a trough of 9% in FY2024 to 15% in FY2026, though still below the 28% peak in FY2020.
• The cash conversion cycle improved to 70 days in FY2026 from 103 days in FY2022, indicating better working capital management.
• Working capital days spiked to 165 days in FY2026 (from 77 days in FY2025), which warrants monitoring — this could be driven by higher receivables or inventory build-up.
• Inventory days at 90 and debtor days at 74 are in line with historical averages.

Shareholding Pattern: Stable Promoter, Mixed Institutional

Quarterly Shareholding Trend

Key shareholding insights:

• Promoter holding has been remarkably stable at ~45%, gradually increasing from 44.47% in FY2017 to 45.22% in FY2026.
• FII holding peaked at 11.22% in Dec 2024 but has since declined to 7.50% in Mar 2026, indicating foreign selling.
• DII holding has increased to 25.89% from 23.62% a year ago, suggesting domestic institutional buying is absorbing FII selling.
• The number of shareholders has declined from 68,751 in Jun 2023 to 56,855 in Mar 2026, indicating consolidation of holding — typically a positive sign.
• Public holding has remained stable at ~21%.

Peer Comparison

Atul operates in the competitive Indian specialty chemicals space. Here's how it stacks up:

Peer comparison takeaways:

• Atul trades at 29.1x P/E, the lowest among its major peers, suggesting it is relatively undervalued.
• Its ROCE of 14.9% is mid-range — better than Aarti Industries (6.9%), Anupam Rasayan (7.4%), and Gujarat Fluorochem (9.9%), but below Pidilite (31.0%) and Navin Fluorine (21.4%).
• Atul's quarterly profit growth of 66.1% is among the strongest, second only to Navin Fluorine (113.0%).
• The median P/E for the specialty chemicals sector (93 companies) is 29.1x — Atul is trading exactly at the sector median.
• Atul's market cap of ₹19,714 Cr places it as the 5th largest in this peer set.

Investment Thesis: Why Atul Deserves Attention

Strengths

1. Diversified Business Model: Unlike many specialty chemical peers that are concentrated in 1–2 segments, Atul operates across 9 business verticals, providing natural diversification against sector-specific downturns.

2. Nearly Debt-Free Balance Sheet: With borrowings of just ₹183 Cr against total assets of ₹7,900 Cr, Atul has one of the strongest balance sheets in the Indian chemicals space. The debt-to-equity ratio of ~0.03x provides significant financial flexibility.

3. Strong Earnings Recovery: After bottoming at ₹324 Cr in FY2024, net profit has surged to ₹689 Cr in FY2026 — a 113% increase in two years. The TTM profit growth of 39% suggests momentum is intact.

4. Exceptional Cash Generation: Free cash flow of ₹851 Cr in FY2026 is outstanding and provides ample room for dividends, buybacks, or further investment.

5. Stable Promoter Holding: The Lalbhai family's ~45% stake signals long-term commitment. The gradual increase in promoter holding over the years is a positive signal.

6. Valuation Discount: At 29.1x P/E, Atul trades at a significant discount to Pidilite (60.4x), Gujarat Fluorochem (67.5x), Navin Fluorine (53.9x), and Anupam Rasayan (88.7x).

7. Pioneer Status: Being the first company inaugurated by India's first PM and having manufactured many products for the first time in India gives Atul deep institutional knowledge and first-mover advantages.

Risks & Concerns

1. Subdued Long-Term Growth: The 5-year sales CAGR of 11% and 5-year profit CAGR of 1% are underwhelming for a specialty chemicals company. The stock price CAGR of -4% over 5 years reflects this.

2. Low ROE: The 3-year average ROE of 9% is below the 10-year average of 13%, indicating declining capital efficiency. The current ROE of 11.5% is improving but still modest.

3. Working Capital Pressure: The spike in working capital days to 165 (from 77 a year ago) needs monitoring. This could be due to inventory build-up or stretched receivables.

4. FII Selling: Foreign institutional investors have reduced their stake from 11.22% in Dec 2024 to 7.50% in Mar 2026, which has weighed on the stock price.

5. Premium to Book Value: The stock trades at 3.27x book value, which may limit upside if earnings growth falters.

6. Commodity Chemical Exposure: While Atul has specialty chemical businesses, it also has significant exposure to bulk/commodity chemicals, which are subject to cyclical pricing pressures.

Valuation Analysis

Current Valuation Metrics

• P/E Ratio: 29.1x (based on trailing earnings)
• P/B Ratio: 3.27x
• EV/EBITDA: Approximately 15–16x (estimated)
• Dividend Yield: 0.44%

Historical Valuation Context

At the current price of ₹6,696, the stock is trading 14% below its 52-week high of ₹7,793 and 20% above its 52-week low of ₹5,560.

If we annualise the Q4 FY2026 EPS of ₹71.38, the forward EPS run-rate is approximately ₹285, which would imply a forward P/E of ~23.4x — an attractive multiple for a diversified specialty chemicals company with improving fundamentals.

Fair Value Estimate

Given the improving earnings trajectory, strong balance sheet, and peer valuation discount, a fair P/E range of 30–35x appears reasonable. On a forward EPS of ₹230–250, this translates to a fair value range of ₹6,900–₹8,750, suggesting 3–31% upside from current levels.

Recent Developments & Outlook

• Q4 FY2026 results were the strongest ever, with record revenue of ₹1,670 Cr and record net profit of ₹211 Cr.
• Operating margins have stabilised at 16–17%, up from the 12–14% trough in FY2023–24.
• The capex cycle appears to be peaking, with CWIP declining from ₹1,033 Cr in FY2023 to ₹110 Cr in FY2026. This should drive higher free cash flow going forward.
• Investments have grown to ₹2,592 Cr, which could unlock value through monetisation or dividend income.
• The company's presence in pharma intermediates and agrochemicals positions it well for the China+1 supply chain diversification trend.

Conclusion

Atul Ltd is a classic case of a quality compounder going through a cyclical trough and emerging stronger. After a difficult FY2023–24 marked by margin compression and inventory destocking, the company has delivered a remarkable earnings recovery with FY2026 net profit of ₹689 Cr — an all-time high.

The stock's P/E of 29.1x — at par with the sector median — does not fully reflect the diversification advantage, nearly debt-free balance sheet, improving ROCE, and strong free cash flow generation. The negative 5-year stock price CAGR presents a potential opportunity for long-term investors who believe in the company's business model and management quality.

For investors with a 3–5 year horizon, Atul offers a compelling combination of value (reasonable P/E), quality (strong balance sheet), and growth (earnings recovery momentum). The key risk remains the modest long-term growth trajectory and the need for sustained margin improvement to justify a re-rating.

At ₹6,696, Atul is a 'Buy on Dips' candidate for patient investors seeking exposure to India's diversified specialty chemicals sector with a margin of safety.